Investigating immune interactions in lung cancer
Project 1: Delta immune Ecology of NSCLC
This study is looking at how tumors in non-small cell lung cancer with KRAS mutations interact with the immune system, so we can find out which patients might respond best to immunotherapy and create more personalized treatment plans just for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10930171 on NIH RePORTER |
What this research studies
This research focuses on understanding how tumors interact with the immune system in non-small cell lung cancer (NSCLC), particularly in cases with KRAS mutations. By analyzing pre-treatment and on-treatment biopsies, the study aims to identify unique immune patterns that can predict how well patients will respond to immunotherapy. Advanced computational techniques will be used to analyze the spatial relationships between tumor cells and immune cells, potentially leading to more effective treatment strategies. The goal is to develop biomarkers that can guide personalized therapy based on individual tumor-immune interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRAS-mutant non-small cell lung cancer who are undergoing immunotherapy.
Not a fit: Patients with non-KRAS-mutant lung cancers or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for lung cancer patients, enhancing their response to therapies.
How similar studies have performed: Previous research has shown promise in understanding tumor-immune interactions, but this approach is innovative and aims to provide new insights into treatment responses.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Anderson, Alexander Robertson Allan — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Anderson, Alexander Robertson Allan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.